28
2020-06
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with JD Pharmacy
真人直营投注网站 announced that it has signed a strategic cooperation framework agreement with JD Pharmacy, the pharmaceutical retail channel under JD Health, in a concerted effort to create a patient-centred online innovative healthcare ecosystem. JD Pharmacy will utilise its abundant traffic and resources and strong technological and supply chain capabilities to assist Kintor Pharmaceutical in the marketing and sales of the innovative External use drug KX-826.
22
2020-05
Kintor Pharmaceutical successfully listed on HKEX today
真人直营投注网站 (Stock Code:9939.HK) has successfully been listed on the Main Board of the Stock Exchange of Hong Kong Limited on 22,May 2020.
16
2020-04
Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement
Suzhou Kintor Pharmaceutical ,Inc. ("Kintor Pharmaceutical ")and Sinopharm Holding Co., Ltd. signed the strategic cooperation agreement on the innovation of topical drug Pyrilutamide (KX-826) in Shanghai. Both sides carry out all-round cooperation on patient-centered product design, future business channel development and terminal services, so as to prepare for future market development and better service for patients.
17
2020-02
Suzhou Kintor Obtained Approval to Conduct Clinical Trials for SMO Antagonists in China
On February 17, 2020, National Medical Products Administration officially granted the clinical trials notification to Suzhou Kintor Pharmaceuticals, Inc.(hereinafter referred to as “Suzhou Kintor") and agreed to approve clinical trials to be conducted on the SMO antagonist, GT1708F.
13
2019-12
Ms. Lu Yan Serves as Kintor's Chief Financial Officer
[Suzhou, December 13, 2019] 真人直营投注网站 and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls
25
2019-10
[Suzhou, China, October 25, 2019] 真人直营投注网站 (the parent company of Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor")) and its subsidiaries (the "Group")announced completion of a financing of USD45 million in September 2019, which was a new round of financing after Series C investment of RMB288 million in February 2018. This round of investment was led by the Shanghai Free Trade Zone Fund, followed by Huajin Capital, CCB Technological Innovation Fund, Yicheng Hongtai, Yirongchuang and Guangzhou Chengfa. The original investor, Highlight Medical, also participated in this round of investment.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn